Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | VNN1 | O95497 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.30 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449776 | 0.85 | CCR1 (0.42) | CCR1LMNA | |
| SCHEMBL3450233 | 0.84 | TP53 (0.34) | TP53 | |
| SCHEMBL14541259 | 0.82 | LMNA (0.38) | CCR1TP53LMNA | |
| SCHEMBL947679 | 0.80 | TP53 (0.53) | TP53 | |
| SCHEMBL3447811 | 0.77 | CCR1 (0.39) | CCR1CNR2TP53VNN1LMNA | |
| SCHEMBL6014992 | 0.76 | CCR1 (0.42) | CCR1CNR2TP53VNN1 | |
| SCHEMBL6014963 | 0.73 | F10 (0.51) | CCR1CNR2VNN1 | |
| SCHEMBL3449437 | 0.72 | CCR1 (0.38) | CCR1CNR2VNN1 | |
| SCHEMBL6015018 | 0.72 | CCR1 (0.41) | CCR1CNR2TP53VNN1 | |
| SCHEMBL6015101 | 0.72 | CCR1 (0.42) | CCR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | CCR1 2570/4885CNR2 149/4885TP53 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.